Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protectin...
Main Authors: | Anthony T. P. Chan, Sydney C. W. Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Nephrology
2022-11-01
|
Series: | Kidney Research and Clinical Practice |
Subjects: | |
Online Access: | http://www.krcp-ksn.org/upload/pdf/j-krcp-21-285.pdf |
Similar Items
-
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
by: Alessio Mazzieri, et al.
Published: (2024-04-01) -
Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
by: Ander Vergara, et al.
Published: (2022-10-01) -
Diabetic kidney disease treatment: new perspectives
by: Li-Li Tong, et al.
Published: (2022-09-01) -
Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
by: M. V. Shestakova, et al.
Published: (2023-11-01) -
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
by: Dong-Lim Kim, et al.
Published: (2023-02-01)